Company news

Processa Pharmaceuticals, Inc. news in 2024

Processa Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results

October 29, 2024

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

October 1, 2024

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

September 2, 2024

Processa Pharmaceuticals Provides Product Pipeline and Financial Update

August 27, 2024

Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri

August 18, 2024

Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer

July 29, 2024

Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer

July 16, 2024

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

June 10, 2024

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

April 29, 2024

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

February 5, 2024

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

January 31, 2024

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

January 25, 2024

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

January 24, 2024

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

January 18, 2024

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

January 17, 2024

Decks in 2024